advertisement
Pfeiffer N 30
Showing records 1 to 25 | Display all abstracts from Pfeiffer N60805 Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT
Lamparter J
Klinische Monatsblätter für Augenheilkunde 2015; 232: 390-394
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Pfeiffer N
Advances in Therapy 2014; 31: 1228-1246
60762 GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57
Wilding C
Journal of Pharmacological Sciences 2015; 127: 298-304
60644 The ophthalmic branch of the gutenberg health study: study design, cohort profile and self-reported diseases
Höhn R; Kottler U
PLoS ONE 2015; 10: e0120476
60762 GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57
Bell K
Journal of Pharmacological Sciences 2015; 127: 298-304
60805 Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT
Schulze A
Klinische Monatsblätter für Augenheilkunde 2015; 232: 390-394
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Traverso CE
Advances in Therapy 2014; 31: 1228-1246
60762 GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57
Funke S
Journal of Pharmacological Sciences 2015; 127: 298-304
60644 The ophthalmic branch of the gutenberg health study: study design, cohort profile and self-reported diseases
Peto T
PLoS ONE 2015; 10: e0120476
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Lorenz K
Advances in Therapy 2014; 31: 1228-1246
60805 Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT
Riedel J; Wasielica-Poslednik J
Klinische Monatsblätter für Augenheilkunde 2015; 232: 390-394
60644 The ophthalmic branch of the gutenberg health study: study design, cohort profile and self-reported diseases
Blettner M
PLoS ONE 2015; 10: e0120476
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Saarela V
Advances in Therapy 2014; 31: 1228-1246
60762 GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57
Beck S
Journal of Pharmacological Sciences 2015; 127: 298-304
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Liinamaa J
Advances in Therapy 2014; 31: 1228-1246
60805 Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT
König J
Klinische Monatsblätter für Augenheilkunde 2015; 232: 390-394
60762 GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57
Pfeiffer N
Journal of Pharmacological Sciences 2015; 127: 298-304
60644 The ophthalmic branch of the gutenberg health study: study design, cohort profile and self-reported diseases
Münzel T
PLoS ONE 2015; 10: e0120476
60805 Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT
Pfeiffer N
Klinische Monatsblätter für Augenheilkunde 2015; 232: 390-394
60644 The ophthalmic branch of the gutenberg health study: study design, cohort profile and self-reported diseases
Blankenberg S
PLoS ONE 2015; 10: e0120476
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Uusitalo H
Advances in Therapy 2014; 31: 1228-1246
60762 GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57
Grus FH
Journal of Pharmacological Sciences 2015; 127: 298-304
60644 The ophthalmic branch of the gutenberg health study: study design, cohort profile and self-reported diseases
Lackner KJ
PLoS ONE 2015; 10: e0120476
60017 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Astakhov Y
Advances in Therapy 2014; 31: 1228-1246
60805 Peripapillary Choroidal Thickness and Choroidal Area in Glaucoma, Ocular Hypertension and Healthy Subjects by SD-OCT
Hoffmann EM
Klinische Monatsblätter für Augenheilkunde 2015; 232: 390-394
